The regulation of aldosterone secretion by leptin: Implications in obesity-related cardiovascular disease

Current Opinion in Nephrology and Hypertension

Volumn 27, Issue 2, 2018, Pages 63-69

  Faulkner, Jessica L ^a   Bruder Nascimento, Thiago ^a   Belin De Chantemèle, Eric J ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

aldosterone; hypertension; leptin; obesity; sex differences

Indexed keywords

ALDOSTERONE; LEPTIN; LEPTIN RECEPTOR;

ADIPOCYTE; ADRENAL GLAND; ALDOSTERONE RELEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; HUMAN; NONHUMAN; OBESITY; POSITIVE FEEDBACK; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; ANIMAL; COMPLICATION; METABOLISM; SECRETION (PROCESS); SEX FACTOR;

ADIPOCYTES; ALDOSTERONE; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LEPTIN; OBESITY; SEX FACTORS;

EID: 85042419456     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000384     Document Type: Review

References (50)

1. Andronico G, Cottone S, Mangano MT, et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001; 25:239-242.
2. Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012; 59:1069-1078.
3. Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999; 60:401-405.
4. Silva MA, Cau SB, Lopes RA, et al. Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus. Clin Sci (Lond) 2015; 129:533-545.
5. Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptinmediated sympathoactivation on cardiovascular function in obese mice. Hypertension 2011; 58:271-279.
6. Schafer N, Lohmann C, Winnik S, et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J 2013; 34:3515-3524.
7. El-Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001; 37:845-850.
8. Bollag WB. Regulation of aldosterone synthesis and secretion. Compr Physiol 2014; 4:1017-1055.
9. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48:239-245.
10. Grim CE, Cowley AW Jr, Hamet P, et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension 2005; 45:766-772.
11. Hiramatsu K, Yamada T, Ichikawa K, et al. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc 1981; 29:25-30.
12. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49:704-711.
13. Muller-Fielitz H, Lau M, Johren O, et al. Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosteronedependent mechanism. Br J Pharmacol 2012; 166:2417-2429.
14. Rocchini AP, Katch VL, Grekin R, et al. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986; 57:613-618.
15. Harada E, Mizuno Y, Katoh D, et al. Increased urinary aldosterone excretion is associated with subcutaneous not visceral, adipose tissue area in obese individuals: A possible manifestation of dysfunctional subcutaneous adipose tissue. Clin Endocrinol (Oxf) 2013; 79:510-516.
16. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17:3438-3446.
17. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003; 100:14211-14216.
18. Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 2015; 132:2134-2145.
19. Huby AC, Otvos L Jr, Belin de Chantemele EJ. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension 2016; 67:1020-1028.
20. Fredersdorf S, Endemann DH, Luchner A, et al. Increased aldosterone levels in a model of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2009; 117:15-20.
21. Hofmann A, Peitzsch M, Brunssen C, et al. Elevated steroid hormone production in the db/db mouse model of obesity and type 2 diabetes. Horm Metab Res 2017; 49:43-49.
22. Silva MA, Bruder-Nascimento T, Cau SB, et al. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol 2015; 6:269.
23. Glasow A, Haidan A, Hilbers U, et al. Expression of Ob receptor in normal human adrenals: differential regulation of adrenocortical and adrenomedullary function by leptin. J Clin Endocrinol Metab 1998; 83:4459-4466.
24. Hoggard N, Mercer JG, Rayner DV, et al. Localization of leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ hybridization. Biochem Biophys Res Commun 1997; 232:383-387.
25. Malendowicz LK, Neri G, Markowska A, et al. Effects of leptin and leptin fragments on steroid secretion of freshly dispersed rat adrenocortical cells. J Steroid Biochem Mol Biol 2003; 87:265-268.
26. Ariyawatkul K, Tepmongkol S, Aroonparkmongkol S, Sahakitrungruang T. Cardio-metabolic risk factors in youth with classical 21-hydroxylase deficiency. Eur J Pediatr 2017; 176:537-545.
27. Haluzik M, Sindelka G, Widimsky J Jr, et al. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 2002; 16:41-45.
28. Urbanet R, Pilon C, Calcagno A, et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin Endocrinol Metab 2010; 95:4037-4042.
29. Judd AM, Call GB, Barney M, et al. Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann N Y Acad Sci 2000; 917:628-637.
30. Path G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997; 82:2343-2349.
31. Bastard JP, Jardel C, Delattre J, et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 1999; 99:2221-2222.
32. Xing Y, RaineyWE, Apolzan JW, et al. Adrenal cell aldosterone production is stimulated by very-low-density lipoprotein (VLDL). Endocrinology 2012; 153:721-731.
33. Isidori AM, Strollo F, More M, et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000; 85:1954-1962.
34. Montague CT, Prins JB, Sanders L, et al. Depot-and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997; 46:342-347.
35. Power ML, Schulkin J. Sex differences in fat storage, fat metabolism, and the health risks from obesity: possible evolutionary origins. Br J Nutr 2008; 99:931-940.
36. Ahima RS, Dushay J, Flier SN, et al. Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 1997; 99:391-395.
37. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341:879-884.
38. Riad-Gabriel MG, Jinagouda SD, Sharma A, et al. Changes in plasma leptin during the menstrual cycle. Eur J Endocrinol 1998; 139:528-531.
39. Ahmed AH, Gordon RD, Ward G, et al. Should aldosterone suppression tests be conducted during a particular phase of the menstrual cycle, and, if so, which phase Results of a preliminary study. Clin Endocrinol (Oxf) 2015; 83:303-307.
40. Lumbers ER, Pringle KG. Roles of the circulating renin-angiotensin-aldosterone system in human pregnancy. Am J Physiol Regul Integr Comp Physiol 2014; 306:R91-R101.
41. Sagawa N, Yura S, Itoh H, et al. Possible role of placental leptin in pregnancy: A review. Endocrine 2002; 19:65-71.
42. Todkar A, Di Chiara M, Loffing-Cueni D, et al. Aldosterone deficiency adversely affects pregnancy outcome in mice. Pflugers Archiv 2012; 464:331-343.
43. Gant NF, Daley GL, Chand S, et al. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52:2682-2689.
44. Briant LJ, Charkoudian N, Hart EC. Sympathetic regulation of blood pressure in normotension and hypertension: when sex matters. Exp Physiol 2016; 101:219-229.
45. Hay M. Sex, the brain and hypertension: brain oestrogen receptors and high blood pressure risk factors. Clin Sci (Lond) 2016; 130:9-18.
46. Lambert EA, Straznicky NE, Dixon JB, Lambert GW. Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity Am J Physiol Heart Circ Physiol 2015; 309:H244-H258.
47. Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009; 360: 44-52.
48. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84:3686-3695.
49. Wang B, Chandrasekera PC, Pippin JJ. Leptin-and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. Curr Diabetes Rev 2014; 10:131-145.
50. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418-424.